A Series of New(E)-2-(6-substituted-2,3-dihydroquinolin-4(1H)-ylidene)-N-(4- substituted-phenyl) hydrazinecarbothioamide derivatives were designed, synthesized, characterized by respective spectral data and evaluated for anti cancer activity. Most of the synthesized compounds showed good in vitro inhibitory activities against MDA-MB-231, HeLa, SMMC-7721. Among the compounds 8e, 8j and 8o having were 6,7-dichloro-2,3-dihydroquinolines fused with N-(4-substitutedphenyl)-hydrazinecarbothioamide showed poent cytotoxic activity at low concentration with IC50 value 1.32±0.12μM, 1.15±0.13μM, 1.24±0.23μM and 1.89±0.18μM, 2.04±0.02μM, 2.27±0.12μM and 1.92±0.25μM, 2.35±0.03μM , 2.20±0.23μM, Compounds 8a, 8b were showed lower cytotoxic property in normal cell lines. The compound 8d, 8i, 8n having 6-nitro-2,3-dihydroquinoline moiety fused with N-(4-substituted-phenyl)-hydrazinecarbothioamide showed less potent anti-cancer activity. Docking studies of all the molecules disclosed close hydrogen bond interactions with the binding site.